RT Journal Article
T1 Determinants of therapeutic lag in multiple sclerosis.
A1 Roos, Izanne
A1 Leray, Emmanuelle
A1 Frascoli, Federico
A1 Casey, Romain
A1 Brown, J William L
A1 Horakova, Dana
A1 Havrdova, Eva Kubala
A1 Debouverie, Marc
A1 Trojano, Maria
A1 Patti, Francesco
A1 Izquierdo, Guillermo
A1 Eichau, Sara
A1 Edan, Gilles
A1 Prat, Alexandre
A1 Girard, Marc
A1 Duquette, Pierre
A1 Onofrj, Marco
A1 Lugaresi, Alessandra
A1 Grammond, Pierre
A1 Ciron, Jonathan
A1 Ruet, Aurélie
A1 Ozakbas, Serkan
A1 De Seze, Jérôme
A1 Louapre, Céline
A1 Zephir, Hélène
A1 Sá, Maria José
A1 Sola, Patrizia
A1 Ferraro, Diana
A1 Labauge, Pierre
A1 Defer, Gilles
A1 Bergamaschi, Roberto
A1 Lebrun-Frenay, Christine
A1 Boz, Cavit
A1 Cartechini, Elisabetta
A1 Moreau, Thibault
A1 Laplaud, David
A1 Lechner-Scott, Jeannette
A1 Grand'Maison, Francois
A1 Gerlach, Oliver
A1 Terzi, Murat
A1 Granella, Franco
A1 Alroughani, Raed
A1 Iuliano, Gerardo
A1 Van Pesch, Vincent
A1 Van Wijmeersch, Bart
A1 Spitaleri, Daniele LA
A1 Soysal, Aysun
A1 Berger, Eric
A1 Prevost, Julie
A1 Aguera-Morales, Eduardo
A1 McCombe, Pamela
A1 Castillo Triviño, Tamara
A1 Clavelou, Pierre
A1 Pelletier, Jean
A1 Turkoglu, Recai
A1 Stankoff, Bruno
A1 Gout, Olivier
A1 Thouvenot, Eric
A1 Heinzlef, Olivier
A1 Sidhom, Youssef
A1 Gouider, Riadh
A1 Csepany, Tunde
A1 Bourre, Bertrand
A1 Al Khedr, Abdullatif
A1 Casez, Olivier
A1 Cabre, Philippe
A1 Montcuquet, Alexis
A1 Wahab, Abir
A1 Camdessanche, Jean-Philippe
A1 Maurousset, Aude
A1 Patry, Ivania
A1 Hankiewicz, Karolina
A1 Pottier, Corinne
A1 Maubeuge, Nicolas
A1 Labeyrie, Céline
A1 Nifle, Chantal
A1 Coles, Alasdair
A1 Malpas, Charles B
A1 Vukusic, Sandra
A1 Butzkueven, Helmut
A1 Kalincik, Tomas
K1 Neurology
K1 multiple sclerosis
K1 observational study
K1 therapeutic lag
AB A delayed onset of treatment effect, termed therapeutic lag, may influence the assessment of treatment response in some patient subgroups. The objective of this study is to explore the associations of patient and disease characteristics with therapeutic lag on relapses and disability accumulation. Data from MSBase, a multinational multiple sclerosis (MS) registry, and OFSEP, the French MS registry, were used. Patients diagnosed with MS, minimum 1 year of exposure to MS treatment and 3 years of pre-treatment follow-up, were included in the analysis. Studied outcomes were incidence of relapses and disability accumulation. Therapeutic lag was calculated using an objective, validated method in subgroups stratified by patient and disease characteristics. Therapeutic lag under specific circumstances was then estimated in subgroups defined by combinations of clinical and demographic determinants. High baseline disability scores, annualised relapse rate (ARR) ⩾ 1 and male sex were associated with longer therapeutic lag on disability progression in sufficiently populated groups: females with expanded disability status scale (EDSS)  Pre-treatment EDSS and ARR are the most important determinants of therapeutic lag.
YR 2021
FD 2021-01-11
LK https://hdl.handle.net/10668/28344
UL https://hdl.handle.net/10668/28344
LA en
DS RISalud
RD Apr 10, 2025